Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab induction in unresectable stage III NSCLC
NCT03102242Phase 2Completed
- Sponsor
- Alliance Foundation Trials
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Alliance Foundation Trials. Started Nov 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03102242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102242.